Periodic Reporting for period 1 - Sea4Market (Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain)
Reporting period: 2024-03-01 to 2025-02-28
Innovative marine compounds-based analgesic for chronic pain
Chronic pain affects 1.6bn globally, making it a leading cause of disability with profound impacts on quality of life. While opioid drugs are highly effective in treating pain, they carry the risk of addiction and other harmful side effects. Biotechnology company Sea4Us has developed Sea4Pain, a groundbreaking drug derived from marine compounds. Sea4Pain holds the potential to alleviate the suffering of billions globally. The EIC-funded Sea4Market project aims to clinically validate Sea4Pain through first-in-human trials and subsequently license the technology to swiftly penetrate the multi-billion euro chronic pain market. EIC support is crucial for the success of this high-risk, high-reward initiative. Sea4Us is a world-class biotechnology company with a focus on translating marine-derived compounds with therapeutic potential for unmet medical needs into pharmaceutical assets. Sea4Us has developed a platform focused on drug discovery and development of novel pharmaceuticals based on its core expertise in ion channels and marine biology. Sea4Us is particularly focussed on developing and commercialising therapies for chronic pain.
Sea4Us has developed a ground-breaking therapeutic drug to treat chronic pain in patients. Chronic pain affects 100 million people across Europe, and has a devastating impact on quality of life. Pain is the most common reason people visit their doctors and a leading cause of disability. It is a source of enormous social and economic burden, costing Europe alone over 500 billion Euros a year. There are many medications on the market for treating chronic pain, but they are either ineffective for most types of chronic pain and/or have adverse side-effects. Opioid drugs are the most effective treatment but also inflict drug addiction, habituation and other noxious side-effects. Our novel analgesic molecule, Sea4Pain, has a novel mechanism of action meaning it is highly effective at treating chronic pain and without any known side effects unlike current drugs on the market. Sea4Pain is a first-in-class drug and has the potential to ease the suffering of billions of people globally.
Sea4Market, will enable us to clinically validate our novel analgesic through completion of First-in-Human trials and out-license our technology. EIC support is essential to deliver this high-risk, high reward project and will enable the sustainable growth of our business. We will re-invest revenues from our licencing deal back into our project pipeline to solve other unmet medical needs and ensure the sustainable growth of our company.
Chronic pain affects 1.6bn globally, making it a leading cause of disability with profound impacts on quality of life. While opioid drugs are highly effective in treating pain, they carry the risk of addiction and other harmful side effects. Biotechnology company Sea4Us has developed Sea4Pain, a groundbreaking drug derived from marine compounds. Sea4Pain holds the potential to alleviate the suffering of billions globally. The EIC-funded Sea4Market project aims to clinically validate Sea4Pain through first-in-human trials and subsequently license the technology to swiftly penetrate the multi-billion euro chronic pain market. EIC support is crucial for the success of this high-risk, high-reward initiative. Sea4Us is a world-class biotechnology company with a focus on translating marine-derived compounds with therapeutic potential for unmet medical needs into pharmaceutical assets. Sea4Us has developed a platform focused on drug discovery and development of novel pharmaceuticals based on its core expertise in ion channels and marine biology. Sea4Us is particularly focussed on developing and commercialising therapies for chronic pain.
Sea4Us has developed a ground-breaking therapeutic drug to treat chronic pain in patients. Chronic pain affects 100 million people across Europe, and has a devastating impact on quality of life. Pain is the most common reason people visit their doctors and a leading cause of disability. It is a source of enormous social and economic burden, costing Europe alone over 500 billion Euros a year. There are many medications on the market for treating chronic pain, but they are either ineffective for most types of chronic pain and/or have adverse side-effects. Opioid drugs are the most effective treatment but also inflict drug addiction, habituation and other noxious side-effects. Our novel analgesic molecule, Sea4Pain, has a novel mechanism of action meaning it is highly effective at treating chronic pain and without any known side effects unlike current drugs on the market. Sea4Pain is a first-in-class drug and has the potential to ease the suffering of billions of people globally.
Sea4Market, will enable us to clinically validate our novel analgesic through completion of First-in-Human trials and out-license our technology. EIC support is essential to deliver this high-risk, high reward project and will enable the sustainable growth of our business. We will re-invest revenues from our licencing deal back into our project pipeline to solve other unmet medical needs and ensure the sustainable growth of our company.
Sea4Us is developing a novel non-opioid analgesic drug to treat moderate and severe chronic pain in patients.
Sea4Market, will enable us to clinically validate our novel analgesic through completion of First-in-Human trials and out-license our technology.
During the first period of Sea4Market...
We established industrial scale production of Sea4Pain, under GLP/GMP conditions. We have also established industrial scale production of Sea4Pain, under GLP/GMP conditions without loss of analgesic efficacy and with no toxic effects. Sea4Pain is now undergoing GLP-tox studies with no concern points of concern in its development so far. We are already in contact with clinical partner and clinical trails are scheduled to start Period 2. Sea4Us has also submitted a provisional application related to Sea4Pain, and PCT will be submitted by Q2, 2025
Sea4Pain will be clinically validated for safety in humans (Phase1 clinical trials) with Sea4Market, breaking a cycle of lack of novel therapeutics towards chronic pain.
Sea4Market, will enable us to clinically validate our novel analgesic through completion of First-in-Human trials and out-license our technology.
During the first period of Sea4Market...
We established industrial scale production of Sea4Pain, under GLP/GMP conditions. We have also established industrial scale production of Sea4Pain, under GLP/GMP conditions without loss of analgesic efficacy and with no toxic effects. Sea4Pain is now undergoing GLP-tox studies with no concern points of concern in its development so far. We are already in contact with clinical partner and clinical trails are scheduled to start Period 2. Sea4Us has also submitted a provisional application related to Sea4Pain, and PCT will be submitted by Q2, 2025
Sea4Pain will be clinically validated for safety in humans (Phase1 clinical trials) with Sea4Market, breaking a cycle of lack of novel therapeutics towards chronic pain.
Chronic pain affects 1.6bn people globally, with impactful deleterious effects in quality of life and employment. It is largely an unmet need, without adequate treatment (defined by combination of efficacy AND safety) available for patients. Sea4Us is developing a first in class analgesic drug for the treatment of moderate to severe chronic pain in patients, Sea4Pain. Current standards of care are either unsafe of with low efficacy. Sea4Pain operates via a novel mechanism of action (PCT/IB2020/056918), through which it provides effective and safe analgesia. Sea4Pain is as effective as opioids, at lower doses, without any observed toxic effect (such as habituation or addiction)
Within Sea4market, Sea4Pain will be clinically validated for safety in humans (Phase1 clinical trials), one step closer to breaking a cycle of lack of novel therapeutics towards chronic pain.
Within Sea4market, Sea4Pain will be clinically validated for safety in humans (Phase1 clinical trials), one step closer to breaking a cycle of lack of novel therapeutics towards chronic pain.